

# A continuous flow generator of acetyl nitrate for the synthesis of nitrofuran-based pharmaceuticals

Hubert Hellwig,<sup>[a]</sup> Loïc Bovy,<sup>[a]</sup> Kristof Van Hecke,<sup>[b]</sup> Cornelis P. Vlaar,<sup>[c]</sup> Rodolfo J. Romañach,<sup>[d]</sup> Md. Noor-E-Alam,<sup>[e]</sup> Allan S. Myerson,<sup>[f]</sup> Torsten Stelzer,<sup>[c,f,g]</sup> and Jean-Christophe M. Monbaliu<sup>\*[a,h]</sup>

- 
- [a] Dr. H. Hellwig, L. Bovy, Prof. Dr. J.-C. M. Monbaliu  
Center for Integrated Technology and Organic Synthesis (CiTOS)  
MolSys Research Unit University of Liège  
B6a, Room 3/19, Allée du Six Août 13, 4000 Liège (Sart Tilman) (Belgium)  
E-mail: [jc.monbaliu@uliege.be](mailto:jc.monbaliu@uliege.be)  
Homepage: <https://www.citos.uliege.be>
- [b] Prof. Dr. K. Van Hecke  
XStruct, Department of Inorganic and Physical Chemistry  
Ghent University, Krijgslaan 281-S3, B-9000 Ghent, Belgium
- [c] Prof. Dr. C. P. Vlaar, Prof. Dr. T. Stelzer  
Department of Pharmaceutical Sciences  
University of Puerto Rico – Medical Sciences Campus  
San Juan, Puerto Rico 00936, United States
- [d] Prof. Dr. R. J. Romañach  
Department of Chemistry  
University of Puerto Rico – Mayagüez  
Mayagüez, Puerto Rico 00681, United States
- [e] Prof. Dr. Md. Noor-E-Alam  
Department of Mechanical and Industrial Engineering,  
College of Engineering, Center for Health Policy and Healthcare Research  
Northeastern University  
Boston, Massachusetts 02115, United States
- [f] Prof. Dr. A. S. Myerson, Prof. Dr. T. Stelzer  
Department of Chemical Engineering  
Massachusetts Institute of Technology  
Cambridge, Massachusetts 02139, United States
- [g] Prof. T. Dr. Stelzer  
Crystallization Design Institute  
Molecular Sciences Research Center  
University of Puerto Rico  
San Juan, Puerto Rico 00926, USA
- [h] Prof. Dr. J.-C. M. Monbaliu  
WEL Research Institute,  
Avenue Pasteur 6, B-1300 Wavre (Belgium)
- 

**Abstract:** Nitrofurfural is a key building block for the synthesis of antimicrobial nitrofurans as active pharmaceutical ingredients. Its synthesis involves the nitration of furfural, a substrate derived from biobased resources. However, furfural has a delicate heteroaromatic backbone. Typical nitrations involve harsh reaction conditions, which often compromise this structure, resulting in poor reproducibility and low yields. Although acetyl nitrate, a mild nitrating agent, is suitable for this task, major deterrents remain. First, its conventional preparation method involves conditions that are not compatible with furfural. Second, significant safety concerns are associated with the unstable and explosive nature of acetyl nitrate. These critical issues are addressed herein. A safe and robust continuous flow platform featuring *in situ* generation of acetyl nitrate for the nitration of furfural to nitrofurfural is reported. The high level of integration and automation enables remote process operation by a single operator. Key furfural-based pharmaceutical intermediates were synthesized with favorable metrics and high reproducibility. The efficiency of this flow platform is demonstrated using a selection of best-selling nitrofuran pharmaceuticals (nifuroxazide, nifurtimox, nitrofurantoin and nitrofural), which were obtained with excellent isolated yields in under five minutes.


## Introduction

The discovery of aromatic nitration using nitric acid in the early 1830s quickly became a cornerstone of organic chemistry, leading to broad industrial implementation.<sup>[1–4]</sup> Nitration reactions are inherently hazardous, often described as the most widespread and powerfully destructive industrial unit process operation. These reactions pose significant risks: they are highly exothermic and prone to thermal runaway, while many nitration (by)products themselves are also classified as potential explosives.<sup>[5,6]</sup> Numerous nitrating cocktails have been developed, each tailored to accommodate specific substrate reactivity or sensitivity (Figure 1a).<sup>[7]</sup> Electron-rich aromatic substrates can undergo nitration with mild reagents, while deactivated aryls require harsher conditions. Heteroaromatics are usually far less resilient owing to their lower aromaticity, often resulting in oxidation, ring opening, polymerization or other side reactions.<sup>[8]</sup>

Among heteroaromatics of wide industrial interest, furfural (2-furaldehyde, **1**) is a furan-derived substrate sourced from biomass waste.<sup>[9,10]</sup> Its interest as a pivotal heteroaromatic building block increased after addition in 2010 by the US Department of Energy (DOE) to a list of industrially relevant biobased platform chemicals.<sup>[11]</sup> The nitration product of furfural (5-nitrofurfural, **2**) is a key intermediate in the preparation of nitrofurans **4**, a family of pharmaceutical active ingredients (APIs) with antimicrobial properties (Figure

1b).<sup>[12]</sup> However, the nitration of **1** is notoriously challenging due to its fragile nature and inability to withstand typical harsh nitrating agents.<sup>[8]</sup>

Although safety concerns in the synthesis of various pharmaceutical drugs have been mitigated with continuous flow technology,<sup>[13–19]</sup> the nitration of furfural as a deactivated heterocyclic substrate has remained a key challenge. Acetyl nitrate (Figure 1a) is among the milder nitrating reagents compatible with **1**. Reports about its generation go back as far as 1884, while its use for the nitration of **1** in batch dates back to at least 1902.<sup>[20,21]</sup> Despite being categorized as mild,<sup>[22]</sup> acetyl nitrate is highly sensitive and can explode at temperatures as low as 60 °C.<sup>[5,22]</sup> While the *ex situ* preparation of acetyl nitrate is considered too dangerous,<sup>[22,23]</sup> *in situ* preparation in batch became a privileged alternative. However, *in situ* generation of acetyl nitrate exposes delicate substrates, such as **1**, to harsh conditions. Solutions to address these issues associated with its generation and use for the production of **2** are described here (Figure 1c).




**Figure 1.** Overall context and strategy. **a.** Common nitration cocktails<sup>[7]</sup> and risk mitigation in flow with selected examples.<sup>[24,25]</sup> Delicate organic backbones such as furfural **1** cannot withstand such harsh conditions. In this context, acetyl nitrate emerges as an opportunity for sensitive substrates. **b.** Biobased furfural **1** is a versatile platform to access important pharmaceutical building blocks. The nitration of **1** to nitrofurans is a very capricious reaction due to its delicate backbone, yet it is an important avenue to nitrofurans APIs **4**. **c.** To address the capricious nitration of **1**, a fully integrated and highly automated flow platform is developed. Notably, it features an in-line generator of acetyl nitrate.

We hereby report a versatile, safe and highly automated continuous flow system featuring an acetyl nitrate generator, a subsequent module for the nitration of **1** and a downstream valorization platform toward nitrofurans pharmaceuticals. This continuous system capitalizes on the assets of flow technology with regards to the handling of reactive species and intermediates. It features a range of technical innovations such as a dedicated filtration and separation unit, and a variety of sensors and Process Analytic Technology (PAT) tools placed at critical points, ensuring process robustness and reproducibility for long runs. While optimized specifically for the nitration of **1**, the system can also accommodate other 5-membered heteroaromatic substrates. The final demonstrator fully integrates the process from **1** to a small library of four marketed nitrofurans pharmaceuticals through advanced process concatenation.

## Results and Discussion

Acetyl nitrate is the mixed anhydride of acetic and nitric acid; it can be prepared according to different protocols.<sup>[21–23]</sup> The safest and most convenient *in situ* protocol relies on a mixture of concentrated nitric acid and acetic anhydride.<sup>[22,26]</sup> In a typical procedure, the desired substrate is premixed with either acetic acid and/or acetic anhydride before the addition of nitric acid, in the presence of a catalytic amount of sulfuric acid.<sup>[24,27]</sup> While the nitration of furfural **1** is described on lab-scale under such conditions in batch,<sup>[28–30]</sup> the reaction lacks reproducibility due to the decomposition of the substrate.<sup>[8]</sup>

We developed a continuous flow generator<sup>[31]</sup> of acetyl nitrate from acetic anhydride and nitric acid with catalytic sulfuric acid using commercially available fluidic components (Figure 2 and Section S3., Supporting Information) made from polymers of either perfluoroalkoxy alkane (PFA) or perfluoroethylene (PTFE). To address the harsh, highly acidic reaction conditions, specifically designed chemically resistant ceramic pressure sensors were developed. A critical feature is the precise control of the flow rate of the >90% nitric acid feed solution, achieved through monitoring of mass decrease over time. An in-line IR module provided a convenient real-time monitoring system for steady state, with the characteristic vibration bands at 780-810 cm<sup>-1</sup> (stretching) and 690-740 cm<sup>-1</sup> (scissoring) (Figure 2).




**Figure 2.** Simplified chart for the acetyl nitrate continuous flow generator (details in Section S6., Supporting Information). The lower left insert illustrates the results from the Density Functional Theory (DFT) mechanistic study (Gaussian 16<sup>[32]</sup>, B3LYP-GD3BJ/6-31+G\*\*/M08HX/6-311++G\*\* level of theory, SMD = acetic anhydride at 273 K, Section S8., Supporting Information). The lower right insert shows in-line FTIR and identification of acetyl nitrate. Structural identity of acetyl nitrate was confirmed by comparison with a sample prepared according to a reference protocol from silver nitrate and acetyl chloride<sup>[21]</sup> and with results from ground state frequency DFT calculations (Section S8., Supporting Information).

The mechanism for the formation of acetyl nitrate, which was studied computationally with Gaussian 16 (Section S8., Supporting Information), involves a diffusion-limited, two-step process. The first step involves the addition of a nitrate anion to protonated acetic anhydride and leads to the formation of an unstable intermediate (Figure 2). The latter decomposes with the concomitant release of acetic acid and the desired mixed anhydride. The optimized conditions for the formation of acetyl nitrate in the novel generator ( $G_1$ ) use neat acetic anhydride (5 equiv. relative to HNO<sub>3</sub>, 0.82 mL min<sup>-1</sup>), and fuming nitric acid (with 3 mol% concentrated sulfuric acid, 0.08 mL min<sup>-1</sup>), with a residence time of 40 s at 15 °C (Figure 2). The output of acetyl nitrate, assuming quantitative conversion, is at 0.1 mol h<sup>-1</sup> (daily productivity of 261 g).

With the optimum conditions for the formation of acetyl nitrate in hand, the direct nitration of **1** was next studied under flow conditions. However, as the strongly deactivating aldehyde group of furfural significantly hinders direct electrophilic aromatic substitution, the nitration of **1** is a rather peculiar process that involves a complex network of intertwined reaction intermediates.<sup>[33]</sup> This sequence of reactions proceeds through the activation of **1** into furfural diacetate (**I**),<sup>[34]</sup> which reacts with acetyl nitrate to yield nitrofurfural triacetate (**II**). **II** is then rearomatized by eliminating acetic acid under basic conditions to obtain nitrofurfural diacetate **III**, which can be considered a protected form of **2** (Figure 3).

Before proceeding with experimental optimization of the nitration reaction, we aimed to have a detailed understanding of the mechanism, as it has been the subject of debate in the literature.<sup>[33–35]</sup> One historical key question has been whether nitration of **1**, with its deactivating aldehyde group, occurs, or whether furfural diacetate (**I**) is the species that is nitrated. We used Gaussian 16 to calculate the energy of the transition states and intermediates of the reaction steps<sup>[32]</sup> (Figure 3, Section S8., Supporting Information). Conceptual Density Functional Theory (CDFT) analysis provided a rational assessment of the global nucleophilicity of **1** ( $N = 1.90$  eV) and **I** ( $N = 2.19$  eV), concluding that furfural diacetate is more nucleophilic than **1** and therefore more suitable for fast nitration.<sup>[36]</sup> This is further strengthened with stronger local nucleophilicities at C-5 for **I** ( $N_5 = 0.60$ ) than for **1** ( $N_5 = 0.46$ ). In solution, acetyl nitrate equilibrates into its ionic counterparts, allowing nitronium species to result in the nitration of **I**.<sup>[22]</sup> Computations indicated that the reaction of **I** with nitronium is diffusion limited, thus associated with extremely fast kinetics. As observed experimentally (Supporting Information), this leads to the formation of nitrofurfural triacetate **II** as a mixture of diastereoisomers (**IIa,b**), with compound **III** as minor component. The latter observation indicated that, quite unexpectedly, the direct rearomatization of cationic intermediate **int-II** was not favored under these conditions. Instead, rearomatization occurred following base treatment on **IIa,b**. It proceeds through two diastereomeric pathways with slightly different activation barriers, both converging to **III**. These computational results align with literature reports and our own observations of different kinetic constants for these substrates.<sup>[37]</sup>

We then addressed the conversion of neat **1** to **III** under flow conditions. The upstream acetyl nitrate generator ( $G_1$ ) was fluidically connected in series to a downstream nitration module assembly  $R_{1-3}$  (Figure 4a, Section S7.4.2., Supporting Information). Pre-cooling loops were added to all feeds connected to  $G_1$  and  $R_1$  to improve robustness, as well as reproducibility. A DIY in-line UV cell, clipped outside the PFA tubing to prevent contact with the harsh reaction medium, was inserted downstream  $R_1$ . The in-line UV cell focused on monitoring relative changes in absorbance over time, thus providing insight into the stability of the continuous nitration reaction in real-time (Section S5.7., Supporting Information).




**Figure 3.** Nitration of furfural with acetyl nitrate ( $\text{AcONO}_2$ ). a. Sequence of reaction steps and intermediates en route to nitrofurfural **2**. The structure Intermediate **IIa** was confirmed through XRD (Section S12., Supporting Information). Global and local nucleophilicities are indicated for compounds **1** and **I** (Section S8., Supporting Information) and are expressed in eV.<sup>[36]</sup> The nitration of **I** was studied computationally with Gaussian 16<sup>[32]</sup> (Section S8., Supporting Information) at the B3LYP-GD3BJ/6-31+G\*\*/M08HX/6-311++G\*\* level of theory (SMD = acetic anhydride, 273 K). The base-induced rearomatization was computed with  $\text{Me}_3\text{N}$  as a model Brønsted base (Section S8., Supporting Information).

Preliminary results under flow conditions gave partial conversion of **1** to a mixture of furfural diacetate **I**, nitrofurfural triacetate **IIa,b**, nitrofurfural diacetate **III** and trace amounts of **2**. To maximize the conversion of **1** and the combined yield of **II+III**, a design of experiment (DoE) approach was followed (Figure 4b). Three critical factors were identified: the excess of acetic anhydride, the concentration of sulfuric acid in nitric acid, and the operational temperature in  $R_1$  (Section S7.4.2., Supporting Information). Optimal parameters for the nitration reaction were identified as follows: for 1 equiv. of neat furfural **1**, 7 equiv. of neat acetic anhydride, 1.4 equiv. of  $\text{HNO}_3$  (>90%) with 3 mol%  $\text{H}_2\text{SO}_4$  (0.45 M solution) are needed to give full conversion of **1** under 2 min at 15 °C. These parameters led to 75% combined HPLC yield for **II** (50%) and **III** (20%), along with 5% of **2**. These conditions slightly reduce the excess of acetic anhydride compared to reported batch protocols.<sup>[28–30]</sup> This excess could be further lowered (5 equiv.) though at the cost of decreasing the yield to 65%.

Subsequent work aimed at increasing the conversion of **IIa,b** into **III**. According to literature precedents in batch, adjustment of the pH to 2.5 is required, followed by heating the crude solution for at least 1 h to 55 °C.<sup>[28–30]</sup> Adaptations were necessary to transpose these conditions under flow; specifically, efforts were undertaken to accelerate the rearomatization under basic conditions. After multiple attempts (Section S7.4.3., Supporting Information), the concomitant injection of a 6 M KOH aqueous solution and 2-methyl tetrahydrofuran was adopted, combined with an additional  $R_3$  module operated at 100 °C.

Under these conditions, complete conversion of **II** and total selectivity toward **III** were achieved within a residence time of 72 s. The optimized concatenated protocol (Figure 4a) was successfully repeated over 60 production campaigns ranging from 30 min to 4 h. It consistently delivered yields of  $75 \pm 3\%$  (92% HPLC purity with ~5% of the desired **2** as major impurity) with a productivity of 53 mmol  $\text{h}^{-1}$  (daily productivity of 307 g). In comparison, previously reported batch processes toward **III** typically achieved yields between 15% and 60%.<sup>[38]</sup>

Additionally, the robustness of our flow process is another strong point. Robustness was evaluated using Glorius' approach,<sup>[39]</sup> assessing the impact of disturbances on key parameters (Figure 4c, Section S7.4.7., Supporting Information).




**Figure 4.** Optimization and robustness of the flow nitration platform. HPLC yields; isolated yields are in brackets; HPLC purities on isolated products are in parentheses. **a.** Simplified flow chart of the continuous flow setup for the nitration of furfural **1** toward intermediate **III**. **b.** Design of experiment (DoE) optimization response curve for the nitration of furfural (**1**). Data generated with 1.4 equiv. of HNO<sub>3</sub> (relative to **1**) and 2 min residence time in R<sub>1</sub>. All samples were processed prior to HPLC analysis using in-line quenching and extraction with the concomitant injection of 1 volume of 4 M NaOH (aq.) and 1 volume of 2-methyl tetrahydrofuran (2 mL min<sup>-1</sup> each). **c.** Robustness evaluation of the developed microfluidic process. Data generated with deviations (OVAT) from the optimum conditions, including the concentration of nitric acid, the HNO<sub>3</sub>/1 stoichiometric ratio, the process temperature in R<sub>1</sub>, the residence time, the quality of furfural and the nature of the solvent. All samples were processed prior to HPLC analysis using in-line quenching and extraction with the concomitant injection of 1 volume of 6 M KOH (aq.) and 1 volume of an organic solvent. The organic solvent was typically 2-methyl tetrahydrofuran unless otherwise specified. **d.** Simplified flow chart of the continuous flow setup for the deacylation of nitrofurfural diacetate **III** toward **2**, emphasizing PAT with real-time, in-line IR reaction monitoring. **e.** Design of experiment (DoE) optimization response curve for the deacylation of intermediate **III**. All experiments were carried with crude **III** as a 0.39 M solution in 2-MeTHF (see also inserts a. and b.). After thermal quench, samples were diluted prior to HPLC analysis. **f.** Details on the automated filtration/separation unit that enables full concatenation of the process from **1** to **2** (Section S5.2., Supporting Information). **g.** Metrics for the fully concatenated process.

Deviations included nitric acid concentration (65% vs. >90%) and equivalents (1 or 2 equiv. vs. 1.4 equiv.), R<sub>1</sub> temperature (0 °C or 30 °C vs. 15 °C), residence time (30 s or 240 s vs. 120 s), furfural freshness (5+ years aged vs. freshly distilled), and solvent type (THF, ethyl acetate, DCM, or MEK vs. 2-MeTHF). The study revealed minimal yield loss (0-10%) for most deviations, demonstrating the process's robustness. Notably, using 65% instead of fuming HNO<sub>3</sub> proved safer, more affordable and chemically more compatible, while skipping furfural distillation offered economic benefits. Flexibility in solvent choice for the extraction of **Ila,b** by substituting biobased 2-MeTHF with other FDA-classified solvents, added practicality. The most critical parameter appeared to be the temperature at which R<sub>1</sub> was operated: at 30 °C instead of 0 °C, the yield dropped significantly by 34%. This analysis complements the DoE and aligns with ICH Q13 guidelines, ensuring reproducibility for continuous API manufacturing.<sup>[40]</sup>

To obtain the desired, deprotected nitrofurfural **2**, the next step focused on the deacylation of **III**, releasing its aldehyde function (Figure 4d,e). This transformation is commonly reported under acidic conditions (both homogeneous and heterogeneous).<sup>[28–30,41,42]</sup> Typical homogeneous batch conditions involve 50% H<sub>2</sub>SO<sub>4</sub> at elevated temperatures (> 100 °C). Preliminary experiments were performed with crude **III** in 2-MeTHF under microwave irradiation (Section S7.2., Supporting Information). Batch-wise conversion of nitrofurfural diacetate **III** into **2** with sulfuric acid required a high temperature, as well as prolonged reaction times (> 1 h), which altogether were associated with extensive degradation. Therefore, the deprotection reaction was transposed to flow chemistry using the crude output of **III** in 2-MeTHF collected from the previous step (Figure 4d) and optimized through DoE (Figure 4e). Deacylation of **III** to **2** and concomitant degradation were considered throughout the optimization round. Both these responses were interdependent and increased with (1) reaction time, (2) reaction temperature, (3) sulfuric acid equivalents and (4) sulfuric acid concentration, leaving a very narrow optimization window. Following the DoE model (Figure 4e), the process was intensified at an elevated temperature of 160 °C. With 1.25 equiv. of H<sub>2</sub>SO<sub>4</sub> as a 9 M solution (infused at 0.12 mL min<sup>-1</sup>), total conversion (90% HPLC yield) was achieved within 45 s of residence time (Section S7.4.8., Supporting Information).

One critical step in achieving full concatenation from **1** was the liquid-liquid extraction of **III** prior to diacetate deprotection (Figure 4f). Membrane separation<sup>[43,44]</sup> was not implementable on the long term due to sporadic solid particle formation; gravity-based separation with optical detection of the interface<sup>[45]</sup> was also very challenging due to the dark coloration of both phases. To address both challenges, an automated filtration/extraction unit was developed (Figure 4f), equipped with magnetic interfacial detection coupled with automated actuators and valves (Section S5.2., Supporting Information). Furthermore, temperature and pressure sensors were placed at critical positions to provide invaluable information on steady state, and any deviations from it. Additionally, additional PAT (in-line FTIR, Figure 4b) was installed at the outlet of  $R_4$  to monitor the final concentration of **2**.

Lastly, efforts to demonstrate the versatility of our nitration flow platform encompassed both expanding the scope to other 5-membered heteroaromatic substrates structurally akin to **1** and demonstrating the preparation of marketed APIs from **2**. Both were successfully achieved (Figure 5).



**Figure 5.** Versatility of the continuous flow nitration platform. HPLC yields; Overall isolated yields in brackets; HPLC purities are indicated in parentheses for compounds **4a-d**. **a.** Scope of the nitration platform on other heteroaryl aldehydes **1'a-c**. The conditions used are the same as for compound **1** (see Figure 4). <sup>1</sup>Compound **III'a** was obtained after  $R_3$  as a 68:32 2-nitro/5-nitro regioisomeric mixture in 70% combined yield (full conversion). <sup>2</sup>Compound **III'b** was obtained after  $R_3$  as a single regioisomer in 80% yield. <sup>3</sup>Compound **2'a** was obtained after  $R_4$  as a mixture of 2-nitro- and 5-nitro regioisomers in 78% combined yield. <sup>4</sup>Compound **2'c** was obtained directly after  $R_3$  as a 4:1 4-nitro/5-nitro regioisomeric mixture, while the deacylation already occurred in  $R^3$ . **b.** Use of the nitration platform for the preparation of 4 representative nitrofurans APIs (**4a-d**) through the coupling of crude **2** and a series of hydrazines **3a-d** (Section S7.4.11., Supporting Information). Nifurtimox **4b** was obtained through a slightly adapted protocol to accommodate its solubility (Section S7.4.12., Supporting Information).

For the scope of other heteroaromatic aldehydes, no further optimization was attempted. The optimal conditions for **1** were transposed to 3-furaldehyde **1'a**, thiophenecarboxaldehyde **1'b** and *N*-methyl-2-pyrrolecarboxaldehyde **1'c**, providing key intermediates for the preparation of various APIs such as netropsin,<sup>[46,47]</sup> distamycin,<sup>[46,47]</sup> and 5-nitrothiophene semicarbazone antifungals and antitumorals (Figure 5a).<sup>[48,49]</sup> The preparation of marketed APIs from **2** was successfully achieved on a selection of best-selling nitrofurans (nifuroxazide **4a**, nifurtimox **4b**, nitrofurantoin **4c** and nitrofurazone **4d**). To this end, the reactor effluent from  $R_4$  was merged with a stream of hydrazines **3** (Figure 5b). The in-line IR concentration monitoring of **2** (Figure 4d) allowed precise adjustment of the flow rates of **3** to maintain equimolarity. The corresponding stoichiometric mixtures were allowed to react in a continuously stirred tank reactor (CSTR). The resulting hydrazones were filtered, washed and dried, yielding **4a-d** in 78-94% isolated yield (46-62% overall isolated yield from **1** over the three steps). The entire process is embedded with data acquisition tools, allowing *in situ* monitoring of its stability,

including critical startup and shutdown procedures. Remote control of individual components is also implemented to ensure high safety and reproducibility of the results (Section S5.6x, Supporting Information), fulfilling the aims of PAT. The system combining both nitration and deacylation was continuously operated for over 4 h, providing a space-time yield of 0.572 kg L<sup>-1</sup> h<sup>-1</sup> for **2**. This system provides, for example, a daily output of 261.4 g (98% HPLC purity) for furantoin **4c** (representing theoretically 5200 daily doses based on a 50 mg API dosage). Additionally, this process also showcases a low E-factor of 18 (pending the recycling of all aqueous and organic effluents).

## Conclusion

We present a highly automated, robust and safe acetyl nitrate generator designed for the nitration of delicate furan derivatives as intermediates for antibiotic and antibacterial nitrofuran production. This approach integrates the assets of flow chemistry, in-line data monitoring and process analytical technology (PAT), computational support provides insights for rationalizing reactivity. The upstream flow setup accommodates various heteroaromatics, while the downstream hydrazine coupling can be adapted to produce four market-leading nitrofuran active pharmaceutical ingredients, showcasing its versatility. Nitrofurantoin, one of the best-selling nitrofuran APIs, is obtained in 94% isolated yield (62% overall from furfural) in under 5 minutes. Favorable metrics are achieved through a holistic approach, incorporating the use of neat feedstock solutions, water and/or biobased 2-methyltetrahydrofuran as reaction medium and widely available chemicals. The high level of integration and automation, featuring a newly developed filtration and liquid/liquid gravity separator unit, chemically resistant sensors and automated valves ensures robustness and reproducibility for this notoriously challenging sequence of reactions. Despite its complexity, the system remains manageable by a single operator and is adaptable for a range of reactions without reconfiguration. This innovative platform significantly reduces reaction time and enhances safety, offering a valuable tool for synthesizing important nitrated compounds in line with modern pharmaceutical industry standards.

## Supporting Information

The Supporting Information is available free of charge: Methods, hardware, experimental protocols, analytical data, and computational data (PDF). The authors have cited additional references within the Supporting Information.<sup>[50–64]</sup>

## Acknowledgements

This research was supported by the U.S. Food and Drug Administration under the FDA BAA-22-00123 program, Award Number 75F40122C00192. The authors acknowledge the University of Liège and the “Fonds de la Recherche Scientifique de Belgique (F.R.S.-FNRS)” (Incentive grant for scientific research MIS under grant No F453020F, JCMM). Computational resources were provided by the “Consortium des Équipements de Calcul Intensif (CÉCI)”, funded by the F.R.S.-FNRS under Grant No. 2.5020.11 and by the Walloon Region. The authors thank Dr. Cedric Malherbe (ULiège) for his help processing the in-line PAT-FTIR data. KVH thanks the Special Research Fund (BOF) – UGent (project: BOF/24J/2023/084).

**Keywords:** Nitration platforms • Furfural • Nitrofurans • Flow Chemistry • Process Analytical Technology

- [1] G. Booth, in *Ullmann's Encyclopedia of Industrial Chemistry*, Wiley, **2000**, [https://doi.org/10.1002/14356007.a17\\_411](https://doi.org/10.1002/14356007.a17_411).
- [2] K. M. Aitken *et al.* in *Science of Synthesis: Houben–Weyl Methods of Molecular Transformations* (eds.: C. A. Ramsden, D. Bellus), Georg Thieme Verlag, Stuttgart, **2007**, 1183–1320.
- [3] H. K. Porter, in *Organic Reactions*, Wiley, **2011**, 455–481.
- [4] T. Kahl, K.-W. Schröder, F. R. Lawrence, W. J. Marshall, H. Höke, R. Jäckh, in *Ullmann's Encyclopedia of Industrial Chemistry*, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, **2000**.
- [5] Thomas L. Guggenheim (ed.), in *Chemistry, Process Design, and Safety for the Nitration Industry*, American Chemical Society, **2013**.
- [6] P. G. Urben (ed.), in *Bretherick's Handbook of Reactive Chemical Hazards*, Elsevier, **2017**, C1 81–882.
- [7] S. Patra, I. Mosiagin, R. Giri, D. Katayev, *Synthesis* **2022**, *54*, 3432–3472.
- [8] Olah, G. A.; Malhotra, R.; Narang, S. C. in *Nitration: Methods and Mechanisms*, VCH: Weinheim, Germany, 1989.
- [9] J. W. Döbereiner, *Annalen der Pharmacie* **1832**, *3*, 141–146.
- [10] F. N. Peters, *Ind. Eng. Chem.* **1936**, *28*, 755–759.
- [11] J. J. Bozell, G. R. Petersen, *Green Chem.* **2010**, *12*, 539–55.
- [12] P.-S. Chu, M. I. Lopez, A. Abraham, K. R. El Said, S. M. Plakas, *J. Agric. Food. Chem.* **2008**, *56*, 8030–8034.
- [13] S. G. Newman, K. F. Jensen, *Green Chem.* **2013**, *15*, 1456.
- [14] J. Tibhe, Y. Sharma, R. A. Joshi, R. R. Joshi, A. A. Kulkarni, *Green Process. Synth.* **2014**, *3*, 279–285.
- [15] C. E. Brocklehurst, H. Lehmann, L. La Vecchia, *Org. Process Res. Dev.* **2011**, *15*, 1447–1453.
- [16] Q. Song, X. Lei, S. Yang, S. Wang, J. Wang, J. Chen, Y. Xiang, Q. Huang, Z. Wang, *Molecules* **2022**, *27*, 5139.
- [17] I. Castillo, J. Rehr, P. Sagmeister, R. Lebl, J. Krusz, S. Celikovic, M. Sipek, D. Kirschneck, M. Horn, S. Sacher, D. Cantillo, J. D. Williams, J. G. Khinast, C. O. Kappe, *J. Process Contr.* **2023**, *122*, 59–68.
- [18] D. Cantillo, M. Damm, D. Dallinger, M. Bauser, M. Berger, C. O. Kappe, *Org. Process Res. Dev.* **2014**, *18*, 1360–1366.
- [19] C. Bürki, M. Künzli, P. Dörwächter, P. Wallquist-Franke, L. Y. Wang, F. Zhang, G. Schäfer, *Org. Process Res. Dev.* **2024**, *28*, 1690–1703.
- [20] M. L. Bouveault, M. A. Wahl, *C. R. Hebd. Seances Acad. Sci.*, **1902**, *134*, 776–777.
- [21] H. Burton, P. F. G. Prail, *J. Chem. Soc.* **1955**, 729–731.
- [22] R. Louw, in *Encyclopedia of Reagents for Organic Synthesis*, John Wiley & Sons, Ltd, Chichester, UK, **2001**.
- [23] A. Pictet A, E. Khotinsky, *Ber. Dtsch. Chem. Ges.* **1907**, *40*, 1163–1166

- [24] M. Köckinger, B. Wyler, C. Aellig, D. M. Roberge, C. A. Hone, C. O. Kappe, *Org. Process Res. Dev.* **2020**, *24*, 2217–2227.
- [25] J. Pelleter, F. Renaud, *Org. Process Res. Dev.* **2009**, *13*, 698–705.
- [26] H. E. Folsom, J. Castrillón, *Synth. Commun.* **1992**, *22*, 1799–1806.
- [27] G. Panke, T. Schwalbe, W. Stürner, S. Taghavi-Moghadam, G. Wille, *Synthesis* **2003**, 2827–2830.
- [28] H. Jin, Y. Geng, Z. Yu, K. Tao, T. Hou, *Pestic. Biochem. Physiol.* **2009**, *93*, 133–137.
- [29] S. M. Taimoory, S. I. Sadraei, R. A. Fayoumi, S. Nasri, M. Revington, J. F. Trant, *J. Org. Chem.* **2018**, *83*, 4427–4440.
- [30] G. A. Gamov, A. N. Kiselev, A. E. Murekhina, M. N. Zavalishin, V. V. Aleksandriiskii, D. Yu. Kosterin, *J. Mol. Liq.* **2021**, *341*, 116911.
- [31] D. Dallinger, B. Gutmann, C. O. Kappe, *Acc. Chem. Res.* **2020**, *53*, 1330–1341.
- [32] Gaussian 16, Revision C.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, **2019**.
- [33] J. G. Michels, K. J. Hayes, *J. Am. Chem. Soc.* **1958**, *80*, 1114–1116.
- [34] M. A. F. M. Rahman, Y. Jahng, *Eur. J. Org. Chem.* **2007**, 379–383.
- [35] A. Gaset, J. P. Gorrichon, *Org. Magn. Reson.* **1981**, *16* 239–241.
- [36] M. Ríos-Gutiérrez, A. Saz Sousa, L. R. Domingo, *J. Phys. Org. Chem.* **2023**, *36*, e4503.
- [37] G. Balina, P. Kesler, J. Petre, Pham Dung, A. Vollmar, *J. Org. Chem.* **1986**, *51*, 3811–3818.
- [38] A. R. Katritzky, E. F. V. Scriven, S. Majumder, R. G. Akhmedova, N. G. Akhmedov, A. V. Vakulenko, *Arkivoc* **2005**, 179–191.
- [39] F. Schäfer, L. Lückemeier, F. Glorius, *Chem. Sci.* **2024**, 14548–14555.
- [40] “ICH guideline Q13 on continuous manufacturing of drug substances and drug products” can be found under <https://www.ich.org/page/quality-guidelines> (accessed on January 12 2025).
- [41] R. Pal, T. Sarkar, S. Khasnobis, *Arkivoc* **2012**, *2012*, 570–609.
- [42] L. N. Palacios-Grijalva, D. Y. Cruz-González, L. Lomas-Romero, E. González-Zamora, G. Ulibarri, G. E. Negrón-Silva, *Molecules* **2009**, *14*, 4065–4078.
- [43] B. Liang, X. He, J. Hou, L. Li, Z. Tang, *Adv. Mater.* **2019**, *31*, 1806090.
- [44] A. Adamo, P. L. Heider, N. Weeranoppanant, K. F. Jensen, *Ind. Eng. Chem. Res.* **2013**, *52*, 10802–10808.
- [45] A. Adamo, R. L. Beingessner, M. Behnam, J. Chen, T. F. Jamison, K. F. Jensen, J.-C. M. Monbaliu, A. S. Myerson, E. M. Revalor, D. R. Snead, T. Stelzer, N. Weeranoppanant, S. Y. Wong, P. Zhang, *Science* **2016**, *352*, 61–67.
- [46] Y. Yamamoto, T. Kimachi, Y. Kanaoka, S. Kato, K. Bessho, T. Matsumoto, T. Kusakabe, Y. Sugiura, *Tetrahedron Lett.* **1996**, *37*, 7801–7804.
- [47] A. I. Khalaf, R. D. Waigh, A. J. Drummond, B. Pringle, I. McGroarty, G. G. Skellern, C. J. Suckling, *J. Med. Chem.* **2004**, *47*, 2133–2156.
- [48] L. N. de Araújo Neto, M. do Carmo Alves de Lima, J. F. de Oliveira, E. R. de Souza, M. D. S. Buonafina, M. N. Vitor Anjos, F. A. Brayner, L. C. Alves, R. P. Neves, F. J. B. Mendonça-Junior, *Chem.-Biol. Interact.* **2017**, *272*, 172–181.
- [49] K. M. Roque Marques, M. R. do Desterro, S. M. de Arruda, L. N. de Araújo Neto, M. do Carmo Alves de Lima, S. M. V. de Almeida, E. C. D. da Silva, T. M. de Aquino, E. F. da Silva-Júnior, J. X. de Araújo-Júnior, M. de M. Silva, M. D. de A. Dantas, J. C. C. Santos, I. M. Figueiredo, M.-A. Bazin, P. Marchand, T. G. da Silva, F. J. B. Mendonça-Junior, *Curr. Top. Med. Chem.* **2019**, *19*, 1075–1091.
- [50] Rigaku Oxford Diffraction, (2022), CrysAlisPro Software system, version 1.171.42.49, Rigaku Corporation, Oxford, UK.
- [51] O.V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, H. Puschmann, *J. Appl. Crystallogr.* **2009**, *42*, 339–341.
- [52] G.M. Sheldrick, *Acta Crystallogr. Sect. 2015*, *A71*, 3–8.
- [53] G.M. Sheldrick, *Acta Crystallogr. Sect. 2015*, *C71*, 3–8.
- [54] P. K. Kancharla, Y. S. Reddy, S. Dharuman, Y. D. Vankar, *J. Org. Chem.* **2011**, *76*, 5832–5837.
- [55] L. Domingo, M. Ríos-Gutiérrez, P. Pérez, *Molecules* **2016**, *21*, 748.
- [56] A. V. Yarkov, “5-nitro-2-thiophenemethanediol diacetate,” can be found under <https://spectrabase.com/compound/9NDyHj4FukQ#JXr4JoAYowY> (accessed on January 12 2025)
- [57] G. Aridoss, K. K. Laali, *J. Org. Chem.* **2011**, *76*, 8088–8094.
- [58] C. Gallardo-Garrido, Y. Cho, J. Cortés-Ríos, D. Vasquez, C. D. Pessoa-Mahana, R. Araya-Maturana, H. Pessoa-Mahana, M. Faundez, *Toxicol Appl. Pharmacol.* **2020**, *401*, 115104.
- [59] M. de la Concepción Foces-Foces, F. H. Cano, R. M. Claramunt, A. Fruchier, J. Elguero, *Bull. Soc. Chim. Belg.* **1988**, *97*, 1055–1066.
- [60] M. Romdhani-Younes, M. M. Chaabouni, *J. Sulfur Chem.* **2012**, *33*, 223–228.
- [61] L. Wechteti, N. H. Mekni, M. Romdhani-Younes, *Heterocycl. Comm.* **2018**, *24*, 187–191.
- [62] M. Jereb, *Green Chem.* **2012**, *14*, 3047–3052.
- [63] L. Brard, R. Jumar Singh, K. Kyu Kwang, G. Saulnier-Sholler, US8193180, **2012**.
- [64] H. Herlinger, K.-H. Mayer (Bayer-AG), DE1670840A1, **1967**



## Entry for the Table of Contents



A robust, automated continuous flow system enables safe, high-yield nitration of furfural to key nitro-furan intermediates using *in situ* acetyl nitrate generation. Demonstrated on representative essential World Health Organization (WHO) active pharmaceutical ingredients (API), this innovative open-source platform ensures rapid synthesis, enhanced safety, and excellent reproducibility, aligning with modern pharmaceutical standards.

### ORCID

H. Hellwig 0000-0003-1212-3879

L. Bovy 0009-0002-7826-1756

K. Van Hecke 0000-0002-2455-8856

C. P. Vlaar 0000-0001-5145-8300

R. J. Romañach 0000-0001-7513-7261

Md. Noor-E-Alam 0000-0001-5353-9710

A. S. Myerson 0000-0002-7468-8093

T. Stelzer 0000-0003-3881-0183

J.-C. M. Monbaliu 0000-0001-6916-8846